TTC Oncology Launches Equity Crowdfunding Campaign on WeFunder to Support Funding of Phase 2 Clinical Trials for Breast Cancer With $100,000 Initial Investment

Key Facts

EDINA, Minn.--()--TTC Oncology (“TTC” or the “Company”), an early-stage biotech company, preparing to enter phase 2 clinical trials, is innovating safer solutions for the treatment of metastatic breast cancer, whose mission is to develop and bring to market a novel, small-molecule therapy to address unmet needs of breast cancer patients, today announced the launch of its equity crowdfunding campaign on WeFunder with an initial investment of $100,000.
About TTC Oncology TTC Oncology is an early-stage biotech company, preparing to enter phase 2 clinical trials, is innovating safer solutions for the treatment of metastatic breast cancer, whose mission is to develop and bring to market a novel, small-molecule therapy to address unmet needs of breast cancer patients.
Forward-looking statements or information in this press release include, but are not limited to the Company’s current focus, the full year 2021 outlook, revenue goals for 2021 and 2022 and the benefits launching new technology on the Company.
Although TTC Oncology believes that the expectations reflected in such forward-looking statements or information are reasonable, undue reliance should not be placed on forward-looking statements because TTC Oncology can give no assurance that such expectations will prove to be correct.